[go: up one dir, main page]

WO2012007622A1 - Méthode de diagnostic différentiel de la maladie de chagas - Google Patents

Méthode de diagnostic différentiel de la maladie de chagas Download PDF

Info

Publication number
WO2012007622A1
WO2012007622A1 PCT/ES2011/070501 ES2011070501W WO2012007622A1 WO 2012007622 A1 WO2012007622 A1 WO 2012007622A1 ES 2011070501 W ES2011070501 W ES 2011070501W WO 2012007622 A1 WO2012007622 A1 WO 2012007622A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
chagas disease
patients
disease
chagas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES2011/070501
Other languages
English (en)
Spanish (es)
Inventor
Mari Carmen Thomas Carazo
Manuel Carlos LÓPEZ LÓPEZ
Concepción MARAÑÓN LIZANA
Ana Isabel FERNÁNDEZ VILLEGAS
Manuel SEGOVIA HERNÁNDEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to MX2013000638A priority Critical patent/MX2013000638A/es
Publication of WO2012007622A1 publication Critical patent/WO2012007622A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Definitions

  • the present invention is within medicine, molecular biology, immunology and parasitology, and refers to a method of obtaining useful data for the differential diagnosis of Chagas disease, allowing to differentiate patients in an undetermined phase from chronic patients. with cardiac and digestive pathologies, as well as to evaluate the response to the treatment of said disease in Chagas patients in chronic cardiac phase.
  • Chagas disease (Chagas-Mazza disease, Chagas disease or American trypanosomiasis), is a tropical parasitic disease mainly from Central and South America, generally chronic and whose etiologic agent is the Trypanosoma cruzi protozoan (T. cruzi). It is estimated to result in about 21,000 deaths each year (WHO, 2002, 2005), with approximately 50,000-200,000 new cases diagnosed per year (Tarleton RL, 2007. PLoS Med 4 (12): e332). Although the disease has traditionally been confined to Latin America, it is currently expanding to non-endemic areas as a result of migratory processes, so it has been necessary to implement diagnostic tests in blood banks and health centers in those countries with a high rate of immigrant population from endemic areas.
  • the incidence of the disease in said immigrant population is 16 per 1,000 in Australia, 9 per 1,000 in Canada, 25 per 1,000 in Spain and 8-50 per 1,000 in the US (Schmun ⁇ s GA et al, 2007. Mem tnst Oswaldo Cruz. 102 Suppl 1: 75-85).
  • T. cruzi is a flagellated parasitic protozoan that belongs to the Kinetoplastid Order and presents an obligatory phase of intracellular multiplication in the vertebrate host, in which it is capable of infecting the different types of cells.
  • the infective form of the parasite or metacyclic trypomastigote is It is found in the gastrointestinal tract of the invertebrate host or insect that transmits the disease and is transmitted to the vertebrate host after the bite of the insect, which, in addition, defecates at the time of the bite, favoring the entry of the parasite by scratching caused by the character stool irritant
  • the metacyclic trypomastigote is visible in the blood as a fusiform tripomastigote, in the form of "C" or "S", 20 ⁇ long by 1 ⁇ wide and has no replicative capacity.
  • the scourge is shortened and transformed into a round amastigote of 2 to 5 ⁇ in diameter.
  • the amastigote is multiplied by binary fission forming "clusters” or “nests” that accumulate in the host cell until it breaks.
  • the parasites released from the cell are transformed into the form of blood trypomastigote and are released into the bloodstream. They have a size that varies between 15 and 20 ⁇ , have free scourge thanks to which they can move, a bulky, terminal or underground cinetoplast, and an oval nucleus.
  • These trypomastigotes can infect other cells to repeat the cycle, but they are not able to multiply in the blood, since the only replicative form in the vertebrate is the intracellular amastigote form.
  • Invertebrate hosts are hematophagous and acquire the parasite by feeding on man or infected domestic or wild animals.
  • the trypomastigotes migrate to the midgut of the insect, where they become epimmastigotes, wide flagellate, very mobile, with the kinetoplast between the nucleus and the free scourge. There they divide a large number of times, leaving the insect infected for life.
  • the ep ⁇ mastigotes migrate to the posterior intestine where, due to the acidity of the area, they are transformed into metacyclic tripomastigotes being excreted with feces at the time of the bite. In the case of infection caused by T, cruzi in man, the disease presents two severe states.
  • the acute phase takes place after the bite of the insect and, although it usually goes unnoticed, it is associated with it approximately 10% mortality.
  • the chronic phase which can develop even after more than ten years, is characterized by the appearance of cardiomegaly, electrocardiographic abnormalities, arrhythmias (Chronic Chagas with cardiac involvement), aperistalsis, megaesophagus and megacolon ⁇ Chronic Chagas with digestive involvement), being able to reach cause death.
  • the acute phase lasts approximately two to three months, progressing to give rise to an asymptomatic chronic phase, currently called an undetermined phase, which is characterized by the persistence of the infection without presenting apparent clinical problems. About 40% of serologically positive cases are in an undetermined phase, which frequently evolves into a chronic symptomatic phase several years later.
  • Chagas disease is routinely diagnosed by various commercial serological methods such as ELISA techniques, indirect immunofluorescence (IFI) or hemagglutination, for which complete or semi-purified protein extracts of the epimastigote forms of the T. cruzi parasite are used, mixtures of recombinant proteins or synthetic peptides corresponding to antigens or antigenic fragments of the parasite (Umezawa et al., 1996. J. Clin Microbiot. 34: 2143-2147; da Silveira et al., 2001. Trend Parasite !. 1 7: 286- 291).
  • Another method of serological diagnosis developed is the so-called ID-PaGIA-Chagas (Rabello et al., 1999.
  • serological diagnostic systems allow antibodies to be detected in sera of chronic patients, but they are not very useful for evaluating the evolution of patients under treatment, since antibody levels persist stably for a long time.
  • the treatment although decreasing the parasite load can influence the reduction of the level of antibodies, destroying the parasite can lead to exposure to the immune system of new parasitic components, with the consequent possible generation of antibodies with other specificities.
  • These two conjugated effects increase in the titer of some antibodies and decrease in others
  • the present invention provides a new marker and a new method of obtaining useful data for the diagnosis of Chagas disease, for the differential diagnosis of the chronic stages (with cardiac or digestive alterations) of the undetermined stage, allowing the establishment of groups of patients according to the degree of the pathology, as well as to monitor and evaluate the response to the treatment and evolution of said disease in patients with chagasic heart disease.
  • Another aspect of the present invention relates to a kit comprising said new marker and the use of said kit for the diagnosis of Chagas disease, for the differential diagnosis of the different clinical forms of said disease and for monitoring the patient and / or evaluation of the state of your disease after the administration of the treatment.
  • This marker makes it possible to differentiate patients with Chagas disease in any of the forms of chronic disease (indeterminate, cardiac, digestive) from those patients with related infectious diseases (leishmaniasis, malaria, tuberculosis).
  • This marker distinguishes patients with chagasic heart disease from those patients with non-chagasic cardiac disorders (acute myocarditis, acute myocardial infarction, idiopathic cardiomyopathy, heart failure, etc.).
  • the present invention provides a solution, under a non-invasive serological technique of easy and rapid realization as well as economical, to the need to identify the phase in which the chagasic patients are, since It allows differentiating patients in chronic phase from patients in undetermined phase.
  • the present invention makes it possible to differentiate whether the patient in the chronic phase has a cardiac or digestive condition from those who do not.
  • a first aspect of the invention relates to a peptide (hereinafter called the peptide of the invention) of amino acid sequence:
  • Xi represents an amino acid that is selected from G and A; where X 2 is a group of 4 amino acids that are selected from A, E and G; where X 3 is a group of 2 amino acids that are selected from S, L, P and A.
  • X 2 is AAX 4 , where X 4 is a group of two amino acids that are selected from A, E and G.
  • X 4 is AA, AG or EG.
  • X 3 is SL, PP, AP or AA.
  • the amino acid sequences are selected from SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO : 6, SEQ ID NO: 7 and SEQ ID NO: 8.
  • the amino acid sequence is SEQ ID NO: 1.
  • a peptide is a molecule formed by the union of several amino acids by peptide bonds.
  • Amino acids are organic molecules that have an amino group and a carboxyl group and are part of the proteins.
  • the amino acids that are part of the proteins are 20, and can be represented by three letters or by a single letter.
  • F is phenylalanine
  • Q is Glutamine
  • D is aspartic acid
  • K is lysine
  • P proline
  • G glycine
  • A is alanine
  • E glutamic acid
  • S serine
  • L leucine
  • said peptide is characterized in that its amino acid sequence comprises the amino acid sequence of the peptide of the invention as described above.
  • the label may be a peptide of the invention flanked by amino acids or other molecules not relevant for its function as a marker, but which may allow anchoring to a solid support so that all relevant antigenic sequence of the peptide is available to be recognized by a antibody.
  • said peptide is characterized in that its sequence is repeated at least twice.
  • the peptide sequence of the invention can be repeated at least twice, each repetition being linked by amino acids or molecules not relevant for the specific recognition of the peptide by the antibodies.
  • a second aspect of the invention relates to the use of the peptide of the invention as a marker for the differential diagnosis, prognosis or monitoring of the stage of Chagas disease in an isolated biological sample.
  • diagnosis and “differential diagnosis”, as used in the present invention, refer to the ability to discriminate between individuals infected by the T. cruzi parasite from those not infected by T. cruzi or infected by other agents. Infectious infections (such as the causes of leishmaniosis, malaria, tuberculosis, etc.). It also refers, but not limited to, the ability to discriminate between samples from patients presenting with different clinical forms of Chagas disease: the acute phase, shortly after infection, the undetermined phase and the chronic phase.
  • prognosis refers to the ability to assign a probability of certain situations occurring in the course of Chagas disease, when a sample classification method is applied. based on the analysis of the amount of antibodies against the peptide of the invention and on the comparison of the amount detected with a reference amount. This assignment, as understood by a person skilled in the art, is not intended to be correct in 100% of the samples analyzed. However, it requires that a statistically significant amount of the analyzed samples be classified correctly. This term refers, for example, but not limited to the probability of developing or suffering from a cardiac pathology or the probability of developing or suffering from a digestive pathology, as well as the prediction of response to a certain treatment of Chagas disease.
  • an "isolated biological sample” refers, but is not limited to, cells, tissues and / or biological fluids of an organism, obtained by any method known to a person skilled in the art.
  • the isolated biological sample is a biological fluid, such as, but not limited to, blood, plasma or blood serum. More preferably, the biological fluid is blood serum.
  • the detection of antibodies against the peptide of the invention in an isolated biological sample of an individual is indicative that it has been or continues to be parasitized by T. cruzi.
  • the term “individual” is not intended to be limiting in any aspect, and may be of any age, sex, physical condition and be originating and / or proceeding from any part of the world.
  • Organisms of the Trypanosoma cruzi species belong to Superuk Eukaryota, Order Kinetoplastida, Family Trypanosomatidae, Genus Trypanosoma and subgenus Schizotrypanum.
  • a third aspect of the invention relates to a method of obtaining useful data for the diagnosis and monitoring of Chagas disease, which comprises:
  • the method of obtaining useful data further comprising:
  • the method of obtaining useful data for the diagnosis or monitoring of Chagas disease also comprises: C. assign the individual in the sample to the group of individuals with Chagas disease, when they present a quantity of antibodies quantified in step (a), greater and statistically significant compared to a reference amount.
  • the measurement of the amount or concentration can be carried out directly or indirectly.
  • Direct measurement refers to the measurement of the amount or concentration of antibodies, based on a signal that is obtained directly from the antibodies, and that is directly correlated with the number of antibody molecules present in the sample.
  • Said signal - which we can also refer to as an intensity signal - can be obtained, for example, by measuring an intensity value of a chemical or physical property of said antibodies.
  • the indirect measurement includes the measurement obtained from a secondary component or a biological measurement system (for example the measurement of cellular responses, ligands, "tags" or enzymatic reaction products).
  • antibody refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, that is, molecules that contain an antigen binding site to which they specifically bind (immunoreact) which can be a natural or chemically synthesized peptide or a natural or recombinant protein, produced and purified by molecular and chemical techniques.
  • immunoglobulin M immunoglobulin M
  • IgD immunoglobulin D
  • IgG immunoglobulin G
  • IgA immunoglobulin A
  • IgE immunoglobulin E
  • comparison refers to, but is not limited to, the comparison of the amount of antibodies against the peptide of the invention in the biological sample to be analyzed, also called the sample. biological problem, with an amount of antibodies against the peptide of the invention of one or more reference samples.
  • the reference sample can be analyzed, for example, simultaneously or consecutively, together with the problem biological sample.
  • the comparison described in section (b) of the method of the present invention can be performed manually or automatically and / or assisted by a computer.
  • reference amount refers to the absolute or relative amount of antibodies against the peptide of the invention that allows to discriminate a certain stage of Chagas disease from the other stages of the disease.
  • Suitable reference amounts can be determined by the method of the present invention from a reference sample that can be analyzed, for example, simultaneously or consecutively, together with the problem biological sample.
  • the reference sample may be the negative controls, that is, the amounts detected by the method of the invention in samples of individuals that have not been parasitized by T. cruzi.
  • the reference amount would be the amount of antibodies against the peptide of the invention detected in patients with undetermined Chagas disease.
  • the reference amount could be, but not limited to, the amount of these antibodies detected in a biological sample of the same individual obtained previously.
  • the sample or reference samples can be, for example, obtained from the serum of a patient with Chagas disease in a certain clinical phase.
  • the reference amount is obtained from a reference sample.
  • the reference quantity can also be obtained, for example, from the normal distribution limits of an amount found in samples obtained from a population of patients with Chagas disease in different phases, using well-known statistical techniques.
  • the amount that is statistically significant can be established by a person skilled in the art by using different statistical tools, for example, but not limited, by determining confidence intervals, determining the p-value, Student's test or discriminant functions of Fisher
  • the confidence intervals are at least 90%, at least 95%, at least 97%, at least 98% or at least 99%.
  • the value of p is less than 0.1, 0.05, 0.01, 0.005 or 0.0001.
  • the present invention allows the disease to be correctly detected in at least 60%, in at least 70%, in at least 80%, or in at least 90% of the subjects of a certain group or population analyzed.
  • Another aspect of the invention is a method for the differential diagnosis of Chagas disease comprising steps (a) and (b) of the method of obtaining useful data of the invention, which further comprises:
  • diagnosis differential refers to discrimination, within Chagas patients, of chronic patients, with cardiac and / or digestive pathologies, of undetermined patients.
  • Another aspect of the invention is a method of monitoring the evolution of Chagas disease in chronic chagasic individuals with heart disease which comprises performing at least twice the sequence of steps (a) and (b) of the method of obtaining useful data from the invention, in biological samples from the same individual, and isolated at different times.
  • the monitoring method is performed post-treatment.
  • neural network refers to the monitoring of the development of the disease, such as, but not limited to, the evaluation of the response to a particular treatment of the disease. Chagas disease.
  • the method of monitoring the evolution of Chagas disease further comprises comparing the amount of antibodies quantified in step (a) before the start of treatment, with the amount of antibodies quantified in step (a) at different times after the start of treatment
  • the quantification of the antibodies is performed by an immunoassay.
  • the immunoassay is an ELISA.
  • the ELISA is an indirect ELISA.
  • immunoassays known in the state of the art are, for example, but not limited to: immunoblot, enzyme-linked immunoadsorbent assay (ELISA), linear immunoassay (LIA), radioimmunoassay (RIA), immunofluorescence, immunohistochemistry or protein microarray.
  • ELISA enzyme-linked immunoadsorbent assay
  • LIA linear immunoassay
  • RIA radioimmunoassay
  • immunofluorescence immunohistochemistry or protein microarray.
  • the ELISA is based on the premise that an immunoreactive can be immobilized on a solid support, then bringing that system into contact with a fluid phase containing the complementary reagent that can bind to a marker compound.
  • ELISA enzyme-linked immunoadsorbent assay
  • LIA linear immunoassay
  • RIA radioimmunoassay
  • immunofluorescence immunohistochemistry or protein microarray.
  • the ELISA is based on the premise that an immunore
  • marker compound refers to a compound capable of giving rise to a chromogenic, fluorogenic, radioactive and / or chemiluminescent signal that allows the detection and / or quantification of the amount of antibodies
  • the marker compound is selected from the list comprising radioisotopes, enzymes, fluorophores or any molecule capable of being conjugated with another molecule or detected and / or quantified directly. This marker compound can bind to the antibody directly, or through another compound.
  • marker compounds that bind directly are, but are not limited to, enzymes such as alkaline phosphatase or peroxidase, radioactive isotopes such as 32 P or 35 S, fluorochromes such as fluorescein or metal particles, for direct detection by colorimetry, auto-radiography , fluorimetry, or metallography, respectively.
  • enzymes such as alkaline phosphatase or peroxidase
  • radioactive isotopes such as 32 P or 35 S
  • fluorochromes such as fluorescein or metal particles
  • kits comprising the peptide of the invention for quantifying antibodies against said peptide in an isolated biological sample.
  • the peptide is immobilized in a solid phase.
  • Another aspect of the invention relates to the use of the kit of the invention for the diagnosis of Chagas disease.
  • Another aspect of the invention relates to the use of the kit of the invention for the differential diagnosis of the stage of Chagas disease.
  • kits of the invention for monitoring Chagas disease after the start of treatment.
  • word "comprises” and its variants are not intended to exclude other technical characteristics, additives, components or steps.
  • Other objects, advantages and features of the invention will be derived partly from the description and partly from the practice of the invention.
  • the following examples and drawings are provided by way of illustration, and are not intended to be limiting of the present invention.
  • Figure 1 It shows the reactivity of sera from chagasic patients against peptide 3973. 50 sera from Chagas disease patients and 28 sera from healthy donors (C-, negative control) were used. Serums from Chagas disease patients recognize this peptide significantly higher (p ⁇ 0.001) in relation to healthy donors. The results shown are those obtained at a dilution of the sera of 1: 800.
  • Figure 2 Shows the specificity of the serological response against peptide 3973 (related infectious diseases). 50 sera from Chagas disease patients, 5 from patients with leishmaniasis, 5 from patients with tuberculosis, 4 from patients with malaria and 28 sera from healthy donors (C-, negative control) were used. The sera of Chagas patients recognize peptide 3973 significantly higher (p ⁇ 0.001) than those of patients with other infectious diseases. The results shown are those obtained at a dilution of the sera of 1: 800. Figure 3. It shows the recognition of peptide 3973 depending on the associated chagasic pathology.
  • Figure 4 Shows the specificity of the serological response against peptide 3973 (other heart diseases).
  • the sera of patients with chronic chagasic or digestive heart disease have a recognition of peptide 3973 significantly higher than those of patients who have other non-chagasic heart disease (p ⁇ 0.001).
  • the results shown are those obtained at a dilution of the sera of 1: 1 .600.
  • Figure 5 It shows the reactivity of the sera of 23 chagasic patients to peptide 3973 before and during treatment with benznidazole (at 3, 6, 9, and 12 months of treatment). Only Chagas patients with chronic chagasic heart disease had a significant decrease in recognition of peptide 3973 (p ⁇ 0.05 at 6 months, p ⁇ 0.1 at 9 months and p ⁇ 0.02 at 12 months of treatment) . The results shown are those obtained at a dilution of the sera of 1: 1 .600.
  • Peptide 3973 was obtained by multiple solid phase synthesis (SMPS) using p-methylbenzhydrylamide (MBHA) resin (Houghten, Proc Nati Acad Sci U S A. 1985 82 (15): 5131-5). The purity of the peptide was analyzed by high pressure liquid chromatography (HPLC), according to the method previously described (Hunkapiller and Hood, Biochemistry. 1978 30; 17 (1 1): 2124-33). ELISA (Enzyme-Linked ImmunoSorbent Assay)
  • PBS Phosphate Buffer Satine
  • Example 1 Reactivity of sera from chagasic patients against peptide 3973 and other peptides with formula FX Q-X2-DKP-X 3
  • the presence of specific antibodies as well as the antibody titer against a synthetic peptide was analyzed by ELISA, smaller in size than 20 amino acids, whose sequence corresponds to a part of the T. cruzi membrane protein (TcMp) (Table 1). It was determined that this was specifically recognized by more than 95% of the sera of chagasic individuals (Tablal).
  • results obtained showed that 7 of these peptides were recognized in the same way and percentage (95%) by the sera of the chagasic patients and that, in 12 of the peptides, the level of recognition decreased from 50% to less than 5 % (Table 1 ). Therefore, the results obtained and represented in Table 1 showed the existence of a 12 amino acid sequence, which is recognized by ELISA and statistically significant by more than 95% of the sera of Chagas patients and not by sera from healthy donors. In addition, the results obtained and shown in Table 1 show the identity and relative position of 5 amino acids contained in the 3973 peptide that are involved in said recognition and that are responsible for it.
  • Table 1 Table of reactivity of peptides analogous to 3973. "N” indicates that the peptide is a natural molecule and “Q” indicates that it is a chimeric molecule.
  • Example 2 The serological response against peptide 3973 is specific to Chagas disease versus other related infectious diseases.
  • the reactivity against peptide 3973 of sera from patients with Chagas disease (50 patients) and 28 healthy donor subjects (called negative controls or C-) was tested, observing that the recognition of peptide 3973, by Chagas patients, It is significantly higher (p ⁇ 0.001) than that of healthy donors (Fig 1).
  • the reactivity against peptide 3973 of sera from patients with Chagas disease (50 patients) and other related and endemic infectious diseases of the regions where Chagas disease is found such as leishmaniasis (5 patients) ), tuberculosis (5 patients) or malaria (4 patients).
  • Serums from patients with Chagas disease were tested against peptide 3973 and D.O. they were represented according to the pathology of each patient (chronic phase with heart disease (CARD), chronic phase with digestive pathology (DIG) and undetermined phase (IND).
  • CARD chronic phase with heart disease
  • DIG chronic phase with digestive pathology
  • IND undetermined phase
  • Significant recognition of the 3973 peptide by Chagas patients regardless of stage of the disease Likewise, it is observed that patients with associated pathology such as chronic chagasic (30 patients) or digestive heart disease (21 patients) recognize this peptide significantly higher (p ⁇ 0.001) than those of Chagas patients who apparently they do not have an associated pathology (30 patients) (Fig.
  • Example 4 The serological response against peptide 3973 is specific to Chagas disease in chronic stage and with evidenced pathology and not other non-chagasic diseases that have associated heart disease 50 sera from Chagas disease patients were tested against peptide 3973 and OD values were represented. They were grouped according to the absence or presence of chagasic pathology of each patient: IND: patients in an undetermined phase without apparent symptoms; CARD: with chronic chagasic heart disease; DIG: with digestive pathology. Patients with non-chagasic heart disease were also included. The results obtained show that the recognition of peptide 3973 by patients with chronic chagasic or digestive heart disease is significantly higher than that of patients with other non-chagasic heart disease (Fig. 4).
  • Example 5 Modifications in the recognition of peptide 3973 induced by treatment with benznidazole depend on the associated chagasic pathology.
  • 50 sera from patients with Chagas disease were tested against peptide 3973 before the start of benznidazole (T0) treatment and, for 23 patients, at regular intervals of 3 months after the start of treatment (at 3, 6, 9 and 12 months post-treatment).
  • the patients were grouped according to the associated chagasic pathology: cardiac, digestive pathology or in indeterminate patients without apparent pathology.
  • a significant decrease in the recognition of peptide 3973 was observed at 6 months (p ⁇ 0.05), 9 months (p ⁇ 0.1) and 12 months (p ⁇ 0.02) post-treatment, only in patients with chronic chagasic heart disease (Fig. 5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne un peptide et une méthode d'obtention de données utiles pour le diagnostic différentiel de la maladie de Chagas, permettant de différencier des patients atteints de maladie de Chagas chronique d'individus sains, sur la base de la détection d'anticorps dirigés contre ledit peptide. Par ailleurs, cette méthode permet de différencier des patients atteints de maladie de Chagas de forme clinique indéterminée des patients atteints de maladie de Chagas avec pathologies cardiaque et digestive. Elle permet en outre de différencier des patients atteints de cardiopathie chagasique de ceux présentant des altérations cardiaques non chagasiques (myocardite, cardiopathies idiopathiques, infarctus du myocarde, etc.). La présente invention permet également d'évaluer la réponse au traitement de ladite maladie chez des patients atteints de maladie de Chagas en phase chronique, et notamment chez des patients présentant des altérations cardiaques. En outre, la présente invention concerne une trousse pour la mise en oeuvre de cette méthode de diagnostic différentiel.
PCT/ES2011/070501 2010-07-16 2011-07-08 Méthode de diagnostic différentiel de la maladie de chagas Ceased WO2012007622A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2013000638A MX2013000638A (es) 2010-07-16 2011-07-08 Metodo de diagnostico diferencial de la enfermedad de chagas.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201031097A ES2373262B1 (es) 2010-07-16 2010-07-16 Método de diagnóstico diferencial de la enfermedad de chagas.
ESP201031097 2010-07-16

Publications (1)

Publication Number Publication Date
WO2012007622A1 true WO2012007622A1 (fr) 2012-01-19

Family

ID=45468968

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2011/070501 Ceased WO2012007622A1 (fr) 2010-07-16 2011-07-08 Méthode de diagnostic différentiel de la maladie de chagas

Country Status (4)

Country Link
CO (1) CO6680643A2 (fr)
ES (1) ES2373262B1 (fr)
MX (1) MX2013000638A (fr)
WO (1) WO2012007622A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156808A3 (fr) * 2017-02-22 2018-10-11 Healthtell Inc. Méthodes de criblage d'infections
US11371990B2 (en) 2016-11-11 2022-06-28 Cowper Sciences Inc. Methods for identifying candidate biomarkers
US11747334B2 (en) 2016-06-20 2023-09-05 Cowper Sciences Inc. Methods for differential diagnosis of autoimmune diseases
US11774446B2 (en) 2016-06-20 2023-10-03 Cowper Sciences Inc. Methods for diagnosis and treatment of autoimmune diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0976763A1 (fr) * 1998-07-30 2000-02-02 Innogenetics N.V. Antigènes und immunoessais pour la maladie de Chagas
WO2000050897A1 (fr) * 1999-02-24 2000-08-31 Corixa Corporation COMPOSES ET METHODES DE DETECTION D'UNE INFECTION PAR $i(T. CRUZI)
WO2009158729A2 (fr) * 2008-06-27 2009-12-30 The Infectious Disease Research Institute Inc. Composés et procédés pour le diagnostic et le traitement de la maladie de chagas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0976763A1 (fr) * 1998-07-30 2000-02-02 Innogenetics N.V. Antigènes und immunoessais pour la maladie de Chagas
WO2000050897A1 (fr) * 1999-02-24 2000-08-31 Corixa Corporation COMPOSES ET METHODES DE DETECTION D'UNE INFECTION PAR $i(T. CRUZI)
WO2009158729A2 (fr) * 2008-06-27 2009-12-30 The Infectious Disease Research Institute Inc. Composés et procédés pour le diagnostic et le traitement de la maladie de chagas

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ABEL L.C.J. ET AL.: "T cell epitope characterization in tandemly repetitive Trypanosoma cruzi B13 protein", MICROBES AND INFECTION, vol. 7, 2005, pages 1184 - 1195, XP005123606, DOI: doi:10.1016/j.micinf.2005.03.033 *
DURANTI M.A. ET AL.: "Trypanosoma cruzi: conformational preferences of antigenic peptides bearing the immunodominant epitope of the B 13 antigen", EXPERIMENTAL PARASITOLOGY, vol. 93, no. 1, 1999, pages 38 - 44 *
GRUBER A. ET AL.: "Trypanosoma cruzi: Characterization of two recombinant antigens with potential application in the diagnosis of Changas' disease", EXPERIMENTAL PARASITOLOGY, vol. 76, no. 1, 1993, pages 1 - 12 *
HOFT D. ET AL.: "Trypanosoma cruzi expresses diverse repetitive protein antigens", INFECCTION AND IMMUNITY, vol. 57, no. 7, 1989, pages 1959 - 1967, XP002577572 *
IBANEZ C. ET AL.: "Multiple Trypanosoma cruzi antigens containing tandemly repeated amino acis sequence motifs", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 30, 1988, pages 27 - 34 *
PEREIRA C. M. ET AL.: "Epitope mapping of a single repetitive unit of the B 13 Trypanosoma cruzi antigen as fusions to Escheruchia coli LamB protein", FEMS MICROBIOLOGY LETTERS, vol. 235, 2004, pages 237 - 242 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11747334B2 (en) 2016-06-20 2023-09-05 Cowper Sciences Inc. Methods for differential diagnosis of autoimmune diseases
US11774446B2 (en) 2016-06-20 2023-10-03 Cowper Sciences Inc. Methods for diagnosis and treatment of autoimmune diseases
US11371990B2 (en) 2016-11-11 2022-06-28 Cowper Sciences Inc. Methods for identifying candidate biomarkers
WO2018156808A3 (fr) * 2017-02-22 2018-10-11 Healthtell Inc. Méthodes de criblage d'infections

Also Published As

Publication number Publication date
ES2373262A1 (es) 2012-02-01
ES2373262B1 (es) 2013-05-06
CO6680643A2 (es) 2013-05-31
MX2013000638A (es) 2013-06-03

Similar Documents

Publication Publication Date Title
AU2011287193B2 (en) Use of HMGB1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
Aguado-Martínez et al. Usefulness of rNcGRA7-and rNcSAG4-based ELISA tests for distinguishing primo-infection, recrudescence, and chronic bovine neosporosis
Salant et al. A cross-sectional survey of anti-Toxoplasma gondii antibodies in Jerusalem cats
Hjøllo et al. Longitudinal cohort study of serum antibody responses towards Giardia lamblia variant-specific surface proteins in a non-endemic area
Afshari et al. Procalcitonin as diagnostic biomarker of sepsis
Rudzińska et al. Clinical usefulness of Western blotting and ELISA avidity for the diagnosis of human toxocariasis
WO2012007622A1 (fr) Méthode de diagnostic différentiel de la maladie de chagas
Vallur et al. Specific antibody responses as indicators of treatment efficacy for visceral leishmaniasis
ES3034860T3 (en) Novel peptides and their use in diagnosis
AU2008262696A1 (en) Methods of selecting host resistant animals
ES2637200T3 (es) Procedimiento para el diagnóstico in vitro y/o monitorización de terapia in vitro de infecciones
Kochanowski et al. Comparative analysis of excretory-secretory antigens of Anisakis simplex, Pseudoterranova decipiens and Contracaecum osculatum regarding their applicability for specific serodiagnosis of human anisakidosis based on IgG-ELISA
Mathur et al. Evaluation of a rapid immunochromatographic test for diagnosis of kala-azar & post kala-azar dermal leishmaniasis at a tertiary care centre of north India
Pinho et al. Saliva ELISA: a method for the diagnosis of chronic Chagas disease in endemic areas
Lim et al. Field evaluation of a rapid diagnostic test to detect antibodies in human toxocariasis
Muqbil et al. Seroprevalence of toxoplasmosis among women in Aden city, Yemen
Viettri et al. Evaluation of commercial kits for the immunological and molecular diagnosis of Chagas disease in endemic areas of Venezuela
Parija et al. A serological study of cysticercosis in patients with HIV
Sulbarán et al. Detection of the Sm31 antigen in sera of Schistosoma mansoni–infected patients from a low endemic area
ES2754282T3 (es) Aductos acetaminofén proteína y procedimientos de uso de los mismos
Aranda-Alvarez et al. Human cysticercosis: risk factors associated with circulating serum antigens in an open community of San Luis Potosi, Mexico
WO2010142829A1 (fr) Méthode d'obtention de données utiles pour le diagnostic différentiel de la maladie de chagas et pour évaluer la réponse au traitement
WO2013007985A1 (fr) Procédé
Jaff et al. fever: a neglected disease in the Middle East
Mahmoud et al. Evaluation of a developed IMB based-ELISA in diagnosis of urinary schistosomiasis in areas at risk in Upper Egypt

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11806341

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/000638

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 13031096

Country of ref document: CO

122 Ep: pct application non-entry in european phase

Ref document number: 11806341

Country of ref document: EP

Kind code of ref document: A1